Announcement PDF ASX Announcement Change of Auditor Sydney Australia, 11 July 2024: Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), (the Company), the company developing a New Class of Synthetic Anti-Infectives, advises that in accordance with Listing Rule 3.16.3, BDO Audit Pty Ltd (BDO Audit) has been appointed as auditor of the Company. The appointment follows the resignation of BDO Audit (WA) Pty Ltd (BDO WA) and ASIC’s consent to the resignation in accordance with s329(5) of the Corporations Act 2001 (Cth) (the Act). The change of auditor arose as a result of BDO WA restructuring its audit practice whereby audits will be conducted by BDO Audit, an authorised audit company, rather than BDO WA. In accordance with s327C of the Act, a resolution will be proposed at the Company’s next Annual General Meeting to confirm the appointment of the Company’s auditor. This announcement has been approved for release by Recce Pharmaceuticals Ltd Board. About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic AntiInfectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer antiinfectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development. Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s antiinfective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.